Xiaodong Zhao

Xiaodong Zhao

Auto-generated profile, based on publicly available information

Xiaodong Zhao

Department of Radiation Oncology Washington University in St. Louis St. Louis Missouri USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
EKEuidam Kim
Euidam Kim
YPYang Kyun Park
Yang Kyun Park
TZTianyu Zhao
Tianyu Zhao
ELEric Laugeman
Eric Laugeman
XZXiaodong Neo Zhao
Xiaodong Neo Zhao
HLHugh Lee
Hugh Lee
Purpose: The quality of on‐board imaging systems, including cone‐beam computed tomography (CBCT), plays a vital role in image‐guided radiation therapy (IGRT) and adaptive radiotherapy. Recently, there has been an upgrade of the CBCT systems fused in the O‐ring linear accelerators called HyperSight, featuring a high imaging performance. As the characterization of a new imaging system is essential, we evaluated the image quality of the HyperSight system by comparing it with Halcyon 3.0 CBCT and providing benchmark data for routine imaging quality assurance.Methods: The HyperSight features ultra‐fast scan time, a larger kilovoltage (kV) detector, a more substantial kV tube, and an advanced reconstruction algorithm. Imaging protocols in the two modes of operation, treatment mode with IGRT and the CBCT for planning (CBCTp) mode were evaluated and compared with Halcyon 3.0 CBCT. Image quality metrics, including spatial resolution, contrast resolution, uniformity, noise, computed tomography (CT) number linearity, and calibration error, were assessed using a Catphan and an electron density phantom and analyzed with TotalQA software.Results: HyperSight demonstrated substantial improvements in contrast‐to‐noise ratio and noise in both IGRT and CBCTp modes compared to Halcyon 3.0 CBCT. CT number calibration error of HyperSight CBCTp mode (1.06%) closely matches that of a full CT scanner (0.72%), making it suitable for adaptive planning. In addition, the advanced hardware of HyperSight, such as ultra‐fast scan time (5.9 s) or 2.5 times larger heat unit capacity, enhanced the clinical efficiency in our experience.Conclusions: HyperSight represented a significant advancement in CBCT imaging. With its image quality, CT number accuracy, and ultra‐fast scans, HyperSight has a potential to transform patient care and treatment outcomes. The enhanced scan speed and image quality of HyperSight are expected to significantly improve the quality and efficiency of treatment, particularly benefiting patients.

22 December 2022 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
XZXiaodong Zhao
Xiaodong Zhao
DSDennis N. Stanley
Dennis N. Stanley
CCCarlos E. Cardenas
Carlos E. Cardenas
JHJoseph Harms
Joseph Harms
RPRichard A. Popple
Richard A. Popple
Background: The clinical introduction of dedicated treatment units for online adaptive radiation therapy (OART) has led to widespread adoption of daily adaptive radiotherapy. OART allows for rapid generation of treatment plans using daily patient anatomy, potentially leading to reduction of treatment margins and increased normal tissue sparing. However, the OART workflow does not allow for measurement of patient‐specific quality assurance (PSQA) during treatment delivery sessions and instead relies on secondary dose calculations for verification of adapted plans. It remains unknown if independent dose verification is a sufficient surrogate for PSQA measurements.Purpose: To evaluate the plan quality of previously treated adaptive plans through multiple standard PSQA measurements.Methods: This IRB‐approved retrospective study included sixteen patients previously treated with OART at our institution. PSQA measurements were performed for each patient's scheduled and adaptive plans: five adaptive plans were randomly selected to perform ion chamber measurements and two adaptive plans were randomly selected for ArcCHECK measurements. The same ArcCHECK 3D dose distribution was also sent to Mobius3D to evaluate the second‐check dosimetry system.Results: All (n = 96) ion chamber measurements agreed with the planned dose within 3% with a mean of 1.4% (± 0.7%). All (n = 48) plans passed ArcCHECK measurements using a 95% gamma passing threshold and 3%/2 mm criteria with a mean of 99.1% (± 0.7%). All (n = 48) plans passed Mobius3D second‐check performed with 95% gamma passing threshold and 5%/3 mm criteria with a mean of 99.0% (± 0.2%).Conclusion: Plan measurement for PSQA may not be necessary for every online‐adaptive treatment verification. We recommend the establishment of a periodic PSQA check to better understand trends in passing rates for delivered adaptive treatments.

21 July 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
APAlex T. Price
Alex T. Price
JSJoshua P. Schiff
Joshua P. Schiff
ELEric Laugeman
Eric Laugeman
BMBorna Maraghechi
Borna Maraghechi
MSMatthew Schmidt
Matthew Schmidt
LHLauren E. Henke
Lauren E. Henke
Our institution was the first in the world to clinically implement MR-guided adaptive radiotherapy (MRgART) in 2014. In 2021, we installed a CT-guided adaptive radiotherapy (CTgART) unit, becoming one of the first clinics in the world to build a dual-modality ART clinic. Herein we review factors that lead to the development of a high-volume dual-modality ART program and treatment census over an initial, one-year period. The clinical adaptive service at our institution is enabled with both MRgART (MRIdian, ViewRay, Inc, Mountain View, CA) and CTgART (ETHOS, Varian Medical Systems, Palo Alto, CA) platforms. We analyzed patient and treatment information including disease sites treated, radiation dose and fractionation, and treatment times for patients on these two platforms. Additionally, we reviewed our institutional workflow for creating, verifying, and implementing a new adaptive workflow on either platform. From October 2021 to September 2022, 256 patients were treated with adaptive intent at our institution, 186 with MRgART and 70 with CTgART. The majority (106/186) of patients treated with MRgART had pancreatic cancer, and the most common sites treated with CTgART were pelvis (23/70) and abdomen (20/70). 93.0% of treatments on the MRgART platform were stereotactic body radiotherapy (SBRT), whereas only 72.9% of treatments on the CTgART platform were SBRT. Abdominal gated cases were allotted a longer time on the CTgART platform compared to the MRgART platform, whereas pelvic cases were allotted a shorter time on the CTgART platform when compared to the MRgART platform. Our adaptive implementation technique has led to six open clinical trials using MRgART and seven using CTgART. We demonstrate the successful development of a dual platform ART program in our clinic. Ongoing efforts are needed to continue the development and integration of ART across platforms and disease sites to maximize access and evidence for this technique worldwide.

29 November 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
XZXiaodong Zhao
Xiaodong Zhao
MBMarkus Baur
Markus Baur
PWPhillip D. H. Wall
Phillip D. H. Wall
ELEric Laugeman
Eric Laugeman
Background: Quality assurance (QA) remains unstandardized for CT‐guided online adaptive radiotherapy (CTgART) platforms (Ethos, Varian Medical Systems, Inc., Palo Alto, CA), as they become more clinically prevalent. A secondary dose calculation software (Mobius3D, Varian Medical Systems, Inc., Palo Alto, CA) is provided for this closed CTgART system. However, the clinical impact of tuning dosimetric leaf gap (DLG) correction values for specific delivery techniques for CTgART secondary dose calculations remains uninvestigated.Purpose: Tuning the DLG correction value for different delivery techniques of the independent secondary dose verification software for adaptive online QA.Methods: A total of 31 volumetric arc therapy (VMAT) and 13 fixed‐gantry intensity modulated radiation therapy (IMRT) plans were selected from representative anatomical sites treated in our clinic. All plans were evaluated on a patient CT dataset and a QA dataset of a solid water phantom with an embedded ion chamber placed at the center in both primary treatment planning systems (TPS) and secondary dose verification software. Primary TPS plan doses were compared with secondary calculation doses on patient CT by calculating 3D gamma passing criteria under different DLG correction values ranging from –2 to 2 mm to determine the optimal DLG correction range. Ion chamber verification measurements were then compared to secondary calculation dose to determine the optimal DLG correction value by minimizing the difference for IMRT and VMAT plans, separately.Results: The optimal DLG correction values for VMAT and IMRT techniques were –0.3 and 0.4 mm respectively for the selected clinical cohort of patients. The mean gamma passing rate between primary and secondary doses for VMAT and IMRT were 99.0% ± 1.0% and 99.9% ± 0.1% with 3%/2 mm and excluding 10% low dose criteria. The mean ion chamber agreement for VMAT and IMRT were 0.0% ± 2.1% and 0.2% ± 1.4%.Conclusion: DLG correction value should be tuned for each delivery technique (VMAT and IMRT) separately to maximize the robustness of CTgART online QA programs.

1 December 2024 in Applied Radiation Oncology
Verified
Journal Article
Closed access
CRChipo Raranje
Chipo Raranje
RMRyan Mueller
Ryan Mueller
APAlex T. Price
Alex T. Price
LHLauren E. Henke
Lauren E. Henke
XZXiaodong Zhao
Xiaodong Zhao
JSJoshua P. Schiff
Joshua P. Schiff
Cone-beam CT-guided adaptive radiation therapy (CTgART) is an emerging treatment paradigm that enables the delivery of online adaptive radiation therapy (ART) using CT-based onboard imaging. Our department installed and implemented a CTgART system in 2019 and has since developed workflows for the delivery of CTgART to a wide variety of disease sites. Herein we describe workflow considerations for implementing a CTgART program with a specific focus on the template-based treatment planning methodology that drives online adaptive plan creation on our department’s CTgART platform (Ethos; Varian Medical Systems, Palo Alto, CA). We describe disease-site-specific information for the delivery of CTgART to the thorax, abdomen, prostate, and bladder, and discuss future directions for this technology, which is becoming increasingly accessible and utilized in radiation oncology.

2 June 2026 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
XZXiaodong Zhao
Xiaodong Zhao
PWPhillip D. Wall
Phillip D. Wall
JMJustin Mikell
Justin Mikell
MSMatthew C. Schmidt
Matthew C. Schmidt
ELEric Laugeman
Eric Laugeman
TMThomas R. Mazur
Thomas R. Mazur
This study aimed to characterize the isocentricity of ring-gantry linacs and evaluate variability across institutions and software. Isocentricity is assessed using vendor-provided and user-defined Winston–Lutz (WL) tests. WL was performed at two institutions on a ring-gantry linac using a custom phantom over 1.5 years. Distal and proximal MLCs were tested, with measurements obtained before and after applying 3D shifts. WL analysis was performed using in-house, commercial (C1–C3), and open-source software. Assessed parameters included the 2D ball bearing (BB)–radiation offset, the 3D offset minimizing 2D errors, and 3D isocenter size. 3D isocenter size was additionally computed using gantry-only fields to remove collimator walkout contributions. Results across institutions showed sub-millimeter agreement among software except for C1 (max 0.99 mm difference). Machine-dependent variations were observed (p < 0.03). Proximal and distal banks demonstrated small but statistically significant differences (p < 0.03) in 2D/3D offsets and isocenter size, with greater walkout in the proximal bank and poorer axis alignment in the distal bank. Collimator-walkout-corrected 3D isocenter size was not statistically different between proximal and distal bank or between pre- and post-3D-offset shift. Isocentricity measurements depended on software, MLC bank, pre-/post-offset correction, and institution. For the tested machines, which showed a mean imaging-to-radiation isocenter coincidence of 0.8 mm and a radiation-isocenter size of 0.7 mm, a minimum targeting margin of 1.5 mm would be appropriate to account for geometric uncertainty. With the results from this study, clinicians can choose their own margins based on their machine characteristics.